Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry
This study demonstrated high and sustained drug survival with high rates of skin clearance and improved quality of life in patients with relatively severe disease treated with brodalumab. Improvements were observed as early as 3 months post-treatment initiation and were sustained for up to 24 months in a real-life setting.
Authors
- Martina Kojanová (ORCID: https://orcid.org/0000-0001-9890-9965)
- Alena Machovcová (ORCID: https://orcid.org/0000-0003-0550-1253)
- Jorga Fialová (ORCID: https://orcid.org/0000-0001-6241-6130)
- Petra Cetkovská (ORCID: https://orcid.org/0000-0002-8807-6768)
- Tomáš Doležal (ORCID: https://orcid.org/0000-0001-5217-4465)
- Eydna Didriksen Apol
- Barbora Turková (ORCID: https://orcid.org/0000-0002-3075-5004)
- Spyridon Gkalpakiotis (ORCID: https://orcid.org/0000-0002-6956-5961)
Institutions
- Charles University (CZ)
- University Hospital in Motol (CZ)
- Apigenex (Czechia) (CZ)
- General University Hospital in Prague (CZ)
- Leo Pharma (Denmark) (DK)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1007/s12325-024-02952-4
- Citations
- 2
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.48
Funders
- Univerzita Karlova v Praze